Considerations for the utility of the CPIC guideline for CYP2D6 genotype and codeine therapy

Clinical Chemistry

Volumn 61, Issue 5, 2015, Pages 775-776

  Crews, Kristine R ^a   Caudle, Kelly E ^a   Dunnenberger, Henry M ^b   Sadhasivam, Senthilkumar ^c   Skaar, Todd C ^d  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CODEINE; CYTOCHROME P450 2D6; HYDROCODONE; OXYCODONE; TRAMADOL; NARCOTIC ANALGESIC AGENT;

ANALGESIA; GENOTYPE; HEALTH CARE PERSONNEL; LETTER; PAIN; PHENOTYPE; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; HUMAN; METABOLISM;

ANALGESICS, OPIOID; CODEINE; CYTOCHROME P-450 CYP2D6; HUMANS; PAIN;

EID: 84929000254     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2014.237412     Document Type: Letter

References (4)

1. Nicholson WT, Formea CM. Clinical Perspective on the Clinical Pharmacogenetics Implementation Consortium Updated 2014 Guidelines for CYP2D6 and Codeine. Clin Chem 2015;61:319-21.
2. Crews KR, Cross SJ, McCormick JN, Baker DK, Molinelli AR, MuMullins R, et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 2011;68:143-50.
3. Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, Basford MA, et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther 2012;92:235-42.
4. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 2014;95:376-82.